Immunogenic epitopes for immunotherapy

Patent metadata

Field	Value
Publication number	US-9511128-B2
Application number	US-201314138421-A
Country	US
Kind code	B2
Filing date	Dec 23, 2013
Priority date	Jul 27, 2007
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.

First claim

The invention claimed is:

1. An activated cytotoxic T lymphocyte (CTL), produced by a method comprising
contacting a CTL in vitro with antigen-loaded human class I or II MHC molecules expressed on a surface of an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen-specific manner,
wherein said antigen is a peptide comprising a sequence of SEQ ID No. 2 having an overall length from 8 to 100 amino acids, and
wherein said activated CTL selectively recognizes a cell, which aberrantly expresses a polypeptide comprising an amino acid sequence of SEQ ID No. 2.

2. A method of inducing an immune response in a patient which target cells aberrantly express a polypeptide comprising an amino acid sequence of SEQ ID No. 2, the method comprising administering to the patient in need thereof an effective number of the cytotoxic T lymphocytes (CTL) of claim 1 .

3. The activated cytotoxic T lymphocyte (CTL) of claim 1 , wherein said antigen-presenting cell is selected from the group consisting of a dendritic cell, a monocyte, a monocyte-derived cell and a macrophage.

4. A therapeutic composition comprising the activated cytotoxic T lymphocyte (CTL) of claim 1 .

5. The method of claim 2 , wherein said cytotoxic T lymphocytes (CTL) are obtained from the patient.

6. The method of claim 2 , wherein said cytotoxic T lymphocytes (CTL) are not obtained from the patient.

7. The method of claim 2 wherein said target cells are tumour cells.

8. The method of claim 7 wherein said tumour cells are selected from the group consisting of glioblastoma, colorectal, pancreatic, lung, renal or gastric cancer cells.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Singh Harpreet
• Walter Steffen
• Weinschenk Toni
• Hilf Norbert
• Schoor Oliver
• Trautwein Claudia

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title